Cargando…

Effects of Different Pulmonary Vasodilators on Arterial Saturation in a Model of Pulmonary Hypertension

BACKGROUND: Approved therapies for pulmonary arterial hypertension can induce oxygen desaturation when administered to patients with secondary forms of pulmonary hypertension (PH), probably due to an increase in ventilation/perfusion mismatch. Thus, so far these treatments have largely failed in sec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Becker, Eva Maria, Stasch, Johannes-Peter, Bechem, Martin, Keldenich, Jörg, Klipp, Alexandra, Schaefer, Katja, Ulbrich, Hannes-Friedrich, Truebel, Hubert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756006/ https://www.ncbi.nlm.nih.gov/pubmed/24015306 http://dx.doi.org/10.1371/journal.pone.0073502

Ejemplares similares

Comparison of different vasodilators, endothelin antagonist, PDE5 inhibitior and sGC stimulators, in an animal model of secondary pulmonary hypertension: effects on “desaturation”
por: Becker, Eva Maria, et al.
Publicado: (2011)

Pulmonary Vasodilator Therapy in Children with Single Ventricle Physiology: Effects on Saturation and Pulmonary Arterial Pressure
por: Jeremiasen, Ida, et al.
Publicado: (2020)

Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
por: Franco, Veronica, et al.
Publicado: (2020)

Effectiveness of pulmonary vasodilators on pulmonary hypertension associated with POEMS syndrome
por: Ohashi, Kana, et al.
Publicado: (2019)

Improvement of pulmonary arterial compliance by pulmonary vasodilator in pulmonary hypertension from combined pulmonary fibrosis and emphysema
por: Kusaka, Kei, et al.
Publicado: (2019)

Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
por: Muzevich, Katie M, et al.
Publicado: (2014)

Oxygen-Sensitivity and Pulmonary Selectivity of Vasodilators as Potential Drugs for Pulmonary Hypertension
por: Morales-Cano, Daniel, et al.
Publicado: (2021)

Peptide-Coated Liposomal Fasudil Enhances Site Specific Vasodilation in Pulmonary Arterial Hypertension
por: Nahar, Kamrun, et al.
Publicado: (2014)

Pulmonary vasodilators can lead to various complications in pulmonary “arterial” hypertension associated with congenital heart disease
por: Chida-Nagai, Ayako, et al.
Publicado: (2020)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Adenosine as pulmonary vasodilator in ARDS
por: Molina, JM, et al.
Publicado: (1998)

Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy
por: May, Adam, et al.
Publicado: (2014)

Acute vasodilator testing: An opportunity to advance the precision care of pulmonary hypertension
por: Cirulis, Meghan M., et al.
Publicado: (2019)

Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis
por: Monfredi, Oliver, et al.
Publicado: (2016)

Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC
por: Becker-Pelster, Eva M., et al.
Publicado: (2022)

Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension
por: Sanges, Sébastien, et al.
Publicado: (2019)

Comparison of intravenous sildenafil with inhaled nitric oxide for acute vasodilator testing in pulmonary arterial hypertension
por: Kumar, Shine, et al.
Publicado: (2022)

Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease
por: Gillmeyer, Kari R., et al.
Publicado: (2021)

The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis
por: Shu, Tingting, et al.
Publicado: (2021)

Children with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension Treated with Pulmonary Vasodilators—The Pediatric Cardiologist Point of View
por: Migdał, Anna, et al.
Publicado: (2021)

Beneficial Effects of Pulmonary Vasodilators on Pre-Capillary Pulmonary Hypertension in Patients with Chronic Kidney Disease on Hemodialysis
por: Kimuro, Keiji, et al.
Publicado: (2022)

Pulmonary vasodilator therapy in sarcoidosis‐associated pulmonary hypertension may decrease lung function decline and mortality
por: Gayen, Shameek, et al.
Publicado: (2023)

Pulmonary arterial hypertension due to pulmonary veno-occlusive disease in systemic sclerosis: Importance of early diagnosis and cautious use of pulmonary vasodilator therapy
por: Koito, Hitoshi
Publicado: (2012)

Inhaled pulmonary vasodilators in refractory hypoxemia
por: Wright, Brian J.
Publicado: (2015)

Compression Stockings Improve Lower Legs Symptom in Patients with Pulmonary Artery Hypertension Treated by Pulmonary Vasodilators—A Pilot Study
por: Nakashima, Naoko, et al.
Publicado: (2023)

Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
por: Morrell, Nicholas W., et al.
Publicado: (2013)

Comparison of Balloon Pulmonary Angioplasty and Pulmonary Vasodilators for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-Analysis
por: Kalra, Rajat, et al.
Publicado: (2020)

Pulmonary vasodilation in acute pulmonary embolism – a systematic review
por: Lyhne, Mads Dam, et al.
Publicado: (2020)

Inhaled pulmonary vasodilators for persistent pulmonary hypertension of the newborn: safety issues relating to drug administration and delivery devices
por: Cosa, Nathan, et al.
Publicado: (2016)

Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide
por: Sugawara, Eri, et al.
Publicado: (2017)

Efficacy and safety of oral pulmonary vasodilators in pulmonary veno‐occlusive disease
por: Nakamura, Junichi, et al.
Publicado: (2022)

Pulmonary vasodilator treatment in pulmonary hypertension due to left heart or lung disease: time for a high-definition picture?
por: Piccari, Lucilla, et al.
Publicado: (2021)

Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: Results from the pulmonary vascular disease phenomics study
por: Naranjo, Mario, et al.
Publicado: (2023)

Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis
por: Langleben, David, et al.
Publicado: (2017)

Right Ventricular Postsystolic Strain Curve Morphology before and after Vasodilator Treatment in Idiopathic Pulmonary Arterial Hypertension
por: Rodríguez-Pérez, Álvaro, et al.
Publicado: (2022)

Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries
por: Jain, Pritesh P, et al.
Publicado: (2014)

Biomarkers in two different animal models of pulmonary arterial hypertension (PAH) under treatment with a cGMP enhancing substance
por: Grupe, Julia, et al.
Publicado: (2011)

Four cases with group 3 out-of-proportion pulmonary hypertension with a favorable response to vasodilators
por: Igarashi, Ayako, et al.
Publicado: (2013)

Prescription Patterns for Pulmonary Vasodilators in the Treatment of Pulmonary Hypertension Associated With Chronic Lung Diseases: Insights From a Clinician Survey
por: Thomas, Christopher A., et al.
Publicado: (2021)

Changes in the Pulmonary Artery Wave Reflection in Dogs with Experimentally-Induced Acute Pulmonary Embolism and the Effect of Vasodilator
por: Yoshida, Tomohiko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jhfvgupn84v2r3am6uo5qbm7m4